Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.61 |
| ▸ | TK2 | O00142 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.54 |
| ▸ | TYMP | P19971 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | HBB | P68871 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9153594 | 0.92 | PYGM (0.58) | PYGMTK2LMNAALDH1A1ALB | |
| SCHEMBL10812613 | 0.90 | PYGM (0.70) | PYGMTK2LMNAALDH1A1ALB | |
| SCHEMBL12103839 | 0.90 | PYGM (0.70) | PYGMTK2LMNAALDH1A1ALB | |
| SCHEMBL14388592 | 0.90 | PYGM (0.70) | PYGMTK2LMNAALDH1A1ALB | |
| SCHEMBL10815567 | 0.90 | PYGM (0.70) | PYGMTK2LMNAALDH1A1ALB | |
| SCHEMBL453142 | 0.90 | PYGM (0.70) | PYGMTK2LMNAALDH1A1ALB | |
| SCHEMBL10340724 | 0.90 | PYGM (0.70) | PYGMTK2LMNAALDH1A1ALB | |
| SCHEMBL2786143 | 0.90 | PYGM (0.70) | PYGMTK2LMNAALDH1A1ALB | |
| SCHEMBL22143517 | 0.90 | PYGM (0.70) | PYGMTK2LMNAALDH1A1ALB | |
| SCHEMBL1983444 | 0.90 | PYGM (0.70) | PYGMTK2LMNAALDH1A1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030230-B2 | Process of purifying phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | claimed |
| US-6756496-B1 | SUCH AS TRIETHYLAMMONIUM-5'-DIMETHOXYTRITYL-3'-THYMIDINE-HYDROGEN PHOSPHONONDITHIOATE FOR USE AS ANTIVIRAL AND ANTICANCER AGENTS | ISIS PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | claimed |
| WO-2004039469-A2 | PROCESS OF PURIFYING PHOSPHORAMIDITES | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040082775-A1 | Process of purifying phosphoramidites | ISIS PHARMACEUTICALS INC. | 2004-04-29 | — | — | US | claimed |
| US-5565555-A | Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues | GILEAD SCIENCES, INC. (US) | 1996-10-15 | — | — | US | claimed |
| US-5194599-A | Forming linkages with nuclosides and nucleotides; viricides, anticarcinogenic agents | GILEAD SCIENCES, INC. (US) | 1993-03-16 | — | — | US | claimed |
| EP-0360609-A2 | Novel hydrogen phosphonodithioate compositions | GILEAD SCIENCES, INC. (US) | 1990-03-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082775-A1 | Process of purifying phosphoramidites | PHOSPHO1, ADAR, POLRMT | PYGM 189/4885TK2 235/4885LMNA 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.